Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Up 9.3% – What’s Next?

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) rose 9.3% on Wednesday . The stock traded as high as $4.68 and last traded at $4.6650. Approximately 2,394,610 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 2,725,978 shares. The stock had previously closed at $4.27.

Trending Headlines about Rocket Pharmaceuticals

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: FDA accelerated approval for KRESLADI, Rocket’s gene therapy for pediatric LAD‑I, removes a key regulatory overhang and enables commercial launch planning for a first‑in‑class treatment in a fatal childhood disorder. ProactiveInvestors: Rocket Pharmaceuticals secures FDA approval for KRESLADI
• Positive Sentiment: Market reaction and coverage: Reuters reports shares jumped after the approval — signaling investor recognition of the regulatory milestone and likely increased buy interest. Reuters: Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
• Positive Sentiment: Analyst action: Chardan Capital reaffirmed a Buy rating and set an $11 price target (implying ~200% upside from current levels), which can bolster investor confidence and act as a catalyst if other firms follow. Benzinga: Chardan reaffirms buy on Rocket
• Positive Sentiment: Broader media/analyst takes emphasize program significance and platform implications — coverage highlights that approval could validate Rocket’s gene‑therapy engine and help de‑risk future programs. BioSpace: Rocket’s gene therapy wins FDA greenlight
• Positive Sentiment: Follow‑on headlines and retail coverage (local press and market sites) amplified the story and attention from traders. Joplin Globe: Rocket Pharmaceuticals Announces FDA Approval Blockonomi: RCKT stock surges after FDA approves
• Positive Sentiment: Unusually heavy call buying (≈7,425 calls, ~+529% vs. average) indicates speculative and directional bullish positioning by options traders ahead of or immediately after the news — adds to short‑term upside pressure and volatility.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on RCKT shares. Morgan Stanley set a $5.00 target price on Rocket Pharmaceuticals in a research note on Thursday, January 8th. Wall Street Zen lowered Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Chardan Capital reaffirmed a “buy” rating and set a $11.00 price objective on shares of Rocket Pharmaceuticals in a research report on Friday. TD Cowen upgraded shares of Rocket Pharmaceuticals to a “hold” rating in a research note on Friday, December 19th. Finally, Cantor Fitzgerald boosted their target price on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.79.

Rocket Pharmaceuticals Price Performance

The firm has a market capitalization of $409.31 million, a P/E ratio of -1.88 and a beta of 0.39. The business has a 50-day moving average of $4.03 and a 200 day moving average of $3.63. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.07.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. During the same period in the prior year, the business posted ($0.62) earnings per share. On average, sell-side analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Gaurav Shah sold 12,279 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,643.49. Following the transaction, the chief executive officer directly owned 1,052,045 shares in the company, valued at $3,482,268.95. This trade represents a 1.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the completion of the sale, the general counsel directly owned 683,376 shares of the company’s stock, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 29,415 shares of company stock worth $97,398. 24.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. raised its holdings in shares of Rocket Pharmaceuticals by 0.5% in the 3rd quarter. Federated Hermes Inc. now owns 627,567 shares of the biotechnology company’s stock worth $2,046,000 after acquiring an additional 3,264 shares during the last quarter. Barclays PLC boosted its stake in Rocket Pharmaceuticals by 2.4% during the 4th quarter. Barclays PLC now owns 153,049 shares of the biotechnology company’s stock valued at $537,000 after purchasing an additional 3,656 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Rocket Pharmaceuticals by 1.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 309,247 shares of the biotechnology company’s stock worth $1,085,000 after purchasing an additional 3,809 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Rocket Pharmaceuticals by 94.4% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 5,926 shares in the last quarter. Finally, Rockefeller Capital Management L.P. raised its stake in shares of Rocket Pharmaceuticals by 7.3% in the second quarter. Rockefeller Capital Management L.P. now owns 96,982 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 6,580 shares during the last quarter. 98.39% of the stock is currently owned by institutional investors and hedge funds.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.